Suppr超能文献

蛋白精氨酸甲基转移酶 3 的别构抑制剂。

An allosteric inhibitor of protein arginine methyltransferase 3.

机构信息

Structural Genomics Consortium, University of Toronto, 101 College Street, MaRS Centre, South Tower, Toronto, ON M5G 1L7, Canada.

出版信息

Structure. 2012 Aug 8;20(8):1425-35. doi: 10.1016/j.str.2012.06.001. Epub 2012 Jul 12.

Abstract

PRMT3, a protein arginine methyltransferase, has been shown to influence ribosomal biosynthesis by catalyzing the dimethylation of the 40S ribosomal protein S2. Although PRMT3 has been reported to be a cytosolic protein, it has been shown to methylate histone H4 peptide (H4 1-24) in vitro. Here, we report the identification of a PRMT3 inhibitor (1-(benzo[d][1,2,3]thiadiazol-6-yl)-3-(2-cyclohexenylethyl)urea; compound 1) with IC50 value of 2.5 μM by screening a library of 16,000 compounds using H4 (1-24) peptide as a substrate. The crystal structure of PRMT3 in complex with compound 1 as well as kinetic analysis reveals an allosteric mechanism of inhibition. Mutating PRMT3 residues within the allosteric site or using compound 1 analogs that disrupt interactions with allosteric site residues both abrogated binding and inhibitory activity. These data demonstrate an allosteric mechanism for inhibition of protein arginine methyltransferases, an emerging class of therapeutic targets.

摘要

PRMT3 是一种蛋白质精氨酸甲基转移酶,通过催化 40S 核糖体蛋白 S2 的二甲基化,影响核糖体的生物合成。虽然 PRMT3 已被报道为细胞质蛋白,但它已被证明可以在体外甲基化组蛋白 H4 肽(H4 1-24)。在这里,我们报告了一种 PRMT3 抑制剂(1-(苯并[d][1,2,3]噻二唑-6-基)-3-(2-环己烯基乙基)脲;化合物 1)的鉴定,该抑制剂通过使用 H4(1-24)肽作为底物筛选 16000 种化合物的文库,其 IC50 值为 2.5 μM。PRMT3 与化合物 1 复合物的晶体结构以及动力学分析揭示了一种变构抑制机制。突变变构位点的 PRMT3 残基或使用破坏与变构位点残基相互作用的化合物 1 类似物都消除了结合和抑制活性。这些数据表明了蛋白质精氨酸甲基转移酶抑制的变构机制,这是一类新兴的治疗靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验